Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Chmielecki, Juliann; Foo, Jasmine; R. Oxnard, Geoffrey; E. Hutchinson, Katherine; Ohashi, Kadoaki; Somwar, Romel; Wang, Lu; Amato, Katherine; E. Arcila, Maria; L. Sos, Martin; D. Socci, Nicholas; Viale, Agnès; de Stanchina, Elisa; S. Ginsberg, Michelle; K. Thomas, Roman; G. Kris, Mark; Inoue, Akira; Ladanyi, Marc; A. Miller, Vincent; Michor, Franziska; Pao, William

doi:10.1126/scitranslmed.3002356

Public

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Published in Science Translational Medicine • Jul 6, 2011

Authors:

Juliann Chmielecki

Jasmine Foo

Geoffrey R. Oxnard

Abstract

Non-small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result o...

Subject

Dosing

Lung cancer

Cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!